BioCentury
ARTICLE | Product Development

Biocon, Mylan look ahead to U.S. launch of insulin glargine as last Lantus patent falls for Sanofi

March 11, 2020 11:09 PM UTC

A district court decision in favor of Biocon and Mylan sets the partners up to launch their version of insulin glargine in the U.S. midyear should the candidate get FDA approval in June.

The partners announced Wednesday that the U.S. District Court of New Jersey invalidated claims for U.S. Patent 9,526,844 held by Sanofi (Euronext:SAN; NASDAQ:SNY) covering Lantus insulin glargine. Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:532523) said the ‘844 patent was the last being asserted against the partners’ Semglee insulin glargine product. ...

BCIQ Company Profiles

Biocon Ltd.

Mylan N.V.

Sanofi